Difficulties in renal anemia treatment. Role of prolonged erythropoietin receptor activators


Cite item

Full Text

Abstract

The difficulties in the treatment of anemia in chronic kidney disease and the potentials of erythropoietin receptor activator metoxypolyethuleneglycol Epo-β (Mircera) are discussed

References

  1. Mc Clellan W., Aronoff S.L., Bolton W.K. et al. The prevalence of anemia in patients with chronic kidney disease. Curr. Med. Ress. Opion. 2004; 20: 1501-1510.
  2. Orbador G.T., Roberts T., St Peter W.L. et al. Trends in anemia at initiator of dialysis in the United States. Kidney Int. 2001; 60: 1875-1884.
  3. Bansal N., Tighiouart H., Weiner D. et al. Anemia as a Risk Factor for Kidney Function Decline in Individuals With Heart Failure. Am. J. Cardiol. 2007; 99: 11-37-1142.
  4. Tong P.C., Kong A.P., So W.Y. et al. Hematocrit, independent of chronic kidney disease, predicts adverse cardiovascular outcomes in clinese patients with type 2 diabetes. Diabetes Care. 2006; 29: 2439-2444.
  5. Kovesdy C.P., Trivedy B.K., Kalantar-Zaden K., Anderson J.E. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int. 2006; 69: 560-564.
  6. Li S., Foley R.N., Collins A. J. Anemia and cardiovascular disease, Hospitalization, and stage renal disease, and death in older patients with chronic kidney disease. Int. Urol. Nephrol. 2005; 37(2): 395-402.
  7. Thorp M.L., Johnson E.S. Effect of anemia on mortality, Cardiovascular Hospitalizations and End Stage Renal Disease among patients with chronic renal desease. Nephrology. 2009; 14: 240-246.
  8. Drueke T.B., Locatelli F., Cyne N. et al. CREATE Investidators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. New. Engl. J. Med. 2006; 355(20): 2071-2084.
  9. Singh A.K., Szczech L., Tang K.L. et al. CHOIR Investidators. Correction of anemia with epoetin alfa of chronic kidney disease. New. Engl. J. Med. 2006; 355(20): 2085-2098.
  10. Besarab A, Bolton W.K., Browne J.K. The effects of normal as compared with low are receiving hemodialysis and epoetin. N. Engl. J. Med. 1998; 339: 584-590.
  11. Besarab A., Goodkin D.A., Nissenson A.R. The Normal Hematocrit. Study Follow-up. N. Engl. J. Med., 2008; 358: 433-434.
  12. Phrommintikul A., Haas S.J., Elsik M., Krum H. Mortality and target haemoglobin concentrations in anemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet. 2007; 369:381-388.
  13. Strippoli G.F., Navaneethan S.D., Craig J.C. Hemoglobin and hematocrit targets for the anemia of chronic kidney disease. Cochrane Database Syst. Rev. 2006; 18(40): CD003967.
  14. Drueke T.B., Locatelli F., Cyne N. et al. CREATE Investidators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. New. Engl. J. Med. 2006; 355(20): 2071-2084.
  15. Singh A.K., Szczech L., Tang K.L. et al. CHOIR Investidators. Correction of anemia with epoetin alfa of chronic kidney disease. New. Engl. J. Med. 2006; 355(20): 2085-2098.
  16. Nissenson A.R., Collins A.J., Hurley J. et al. Opportunities for improving the care of patients with chronic renal insufficiency: current practice patterns. J. Am. Soc. Nephrol. 2001; 12: 1713-1720.
  17. London R., Sols A., Goldberg G.A. et al. Examination of resourse use and clinical Interventions associated with chronic care population. J. Manage Care Pharm. 2003; 9: 248-255.
  18. Cody J., Daly C., Campbell M. et al. Recombinant human erythropoietin for chronic renal failure anemia in pre-dialysis patients. Cochrane Database Syst. Rev. 2005; 3: СD 003266.
  19. Ayus J.C., Go A.S., Valderrabano F. et al. Spanish Group for the Study of the Anemia and Left Ventricular Hypertrophy in Pre-dialysis Patients. Effects of erythropoietin on left ventricular hyretrophy in adults with severe chronic renal failure and hemoglobin < 10 g/dl. Kidney Int 2005; 68(2): 788-795.
  20. Dean B.B., Dylan M., Gano A. Jr. et al. Erythropoiesis-stimulating protein therapy and the decline of renal function: a retrospective analysis of patients with chronic kidney disease. Curr. Med. Res. Opin. 2005; 21: 981-987.
  21. Gouva C., Nicolopoulos P., Ionnidis J., Siamopoulos K. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int. 2004; 66: 753-760.
  22. Lefebvre P., Vekeman F., Sarokhan B. et al. Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease recriving epoetin alfa. Curr. Med. Res. Opion. 2006; 22: 1929-1937.
  23. Милованов Ю.С., Козловская Л.В., Николаев А.Ю., Фомин В.В., Милованова Л.Ю. Анемия у больных с хронической почечной недостаточностью. Лечю врач. 2005; 7: 16-21.
  24. Hunsicker L.G. The consequences and costs of chronic kidney disease before ESRD. J. Am. Soc. Nephrol. 2004; 15: 1363-1364.
  25. Fishbane S., Berns J.S. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int. 2005; 68: 1337-1343.
  26. Heung M., Mueller B.A., Segal J.H. Optimising Anemia Managament in Hospitalized patients with End-Stage renal Disease the Annals of Pharmacotherapy. 2009; 43(20): 276-282.
  27. Rice L., Alfrey C.P. The negative regulation of red cell mass by neocytolysis: physiologyc and pathophysiologic manifestations. Cell. Physiol. Bioshem. 2005; 15: 245-250.
  28. Fishbane S. Recombinant human erythropoietin: has treatment reached its full potential? Semin. Dial. 2006; 19: 1-4.
  29. Ebben J.P., Gilbertson D.T., Foley R.N., Collins A.J. Hemoglobin level variability: assotiation with comorbidity, intrcurrent events, and hospitalizations. Clin. J. Am. Soc. Nephrol. 2006: 1: 1205-1210.
  30. Gilbertson D., Ebben J., Collins A. The effects of hemoglobin variability on hospitalization and mortality. Nephrol. Dial. Transplant. 2006; 21 (suppl 4): iv169 (abstract SP458).
  31. Feldman H.I., Israni R.K., Yang W., Fishbane F., Joffe M. Hemoglobin variability and mortality among hemodialysis patients. J. Am. Soc. Nephrol. 2006: 17: 583A (abstract SA-PO034).
  32. Gilbertson D.T., Ebben J.P., Foley R.N. et al. Hemoglobin level variability: association with mortality. Clin. J. Am. Soc. Nephrol. 2008; 3(10: 133-138.
  33. Roche data on file. Data on file. 2007.
  34. Aranesp Summary of Product Characteristics. Shire Pharmaceuticals Ltd. July 2006.
  35. Halstenson C.E., Macres M., Kats S.A. et al. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin. Pharmacol. Ther. 1991; 50: 702-712.
  36. Gross A.W., Lodish H.F. Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein (NESP). J. Biol. Chem. 2006: 281: 2024-2032.
  37. Sulowicz W., Locatelli F., Ryckenlynck J-P. et al. on behalf of the PROTOS Study Investigators. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic Kidney disease on dialysis converted directly from epoetin one to three times weekly. Clin. J. Am. Soc. Nephrol. 2007; 2: 637-646.
  38. Levin N.W., Fishbane S., Zeig S. et al. Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks or once monthly maintains hemoglobin levels in patients with chronic kidney disease on dialysis. Nephrol. Dial. Transplant. 2006; 21 (Suppl 4): iv11 (abstract SO023).
  39. Locatelli F., Villa G., Francisco A.L.M. et al. on behalf of the BA 16286 Study Investigators. Effect of a continuous erythropoietin receptor activator C.E.R.A. on stable hemoglobin in patients with chronic kidney disease on dialysis once monthly administration. Curr. Med. Res. Opin. 2007; 23: 969-979.
  40. Besarab A., Salifu M.O., Lunde N.M. et al. for the BAS16285 Study Investigators. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic kidney disease. Clin. Ther. 2007; 29: 626-639.
  41. Spinowitz B., Coyne D.W., Fraticelli F. et al. C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks via pre-filled syringe (PFS) maintains stable Hb levels in patients with chronic kidney disease on dialysis. J. Am. Soc. Nephrol. 2006; 17: 395A (PUB376).
  42. Francisco A.L.M., Sulowicz W., Klinder M. et al. BA16260 Study Investigators. Continuous erythropoietin receptor activator (C.E.R.A.) administered at extended administration intervals corrects anemia in patients with chronic kidney disease on dialysis: a randomized, multicenter, multiple-dose, phase II study. Int. J. Clin. Pract. 2006; 60: 1687-1696.
  43. Feldman H.I., Joffe M., Yang W., Israni R.K., Fishbane S. Causal analysis of hemoglobin variability and mortality among hemodialysis patients. J. Am. Soc. Nephrol. 2006: 17: 583A (abstract SA-PO035).
  44. Macdougall I.C., Walker R., Provenzano R. et al. C.E.R.A. (continuous erythropoietin receptor activator) administered at extended administration intervals corrects anemia and maintains stable Hb levels in patients with chronic kidney disease not on dialysis. J. Am. Soc. Nephrol. 2006; 17: 619A (abstract SA-PO208).
  45. Provenzano R., Besarab A., Macdougall I.C. et al. on behalf of the BA 16528 Study Investigators. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study. Clin. Nephrol. 2007; 67: 306-317.
  46. Canaud B., Braun J., Locatelli F. et al.. Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks maintains stable hemoglobin levels in patients with chronic kidney disease on dialysis. Nephrol. Dial. Transplant. 2006; 21 (suppl 4): iv157 (abstract SP425).
  47. Klinder M., Arias M., Vargremezis W. et al. C.E.R.A. (continuous erythropoietin receptor activator) administered at extended administration intervals corrects Hb levels in patients with chronic kidney disease on dialysis. J. Am. Soc. Nephrol. 2006; 17: 620A (abstract SA-PO212).
  48. Шило В.Ю. Мирцера - новая эра в лечении ЭПО-дефицитной анемии. Нефрол. и диал. 2008; (3-4): 192-198.
  49. Macdougall I.C., Gray S.J., Elston O. et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J. Am. Soc. Nephrol. 1999; 10: 2392-2395.
  50. MIRCERA Summary of Product Characteristics. Roche Products Ltd. July 2007.
  51. Saueressing U., Sapede C., De Cock E., Staff time and costs for amemia management wth erytropoietic stimulating agents in patients on hemodialysis. Nephrol. Dioal. Transplant. 2007; 22(Suppl 6): vi347-vi348. .

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies